Scleroderma treatment mostly means managing whichever organs are affected rather than treating the disease as a whole, since no therapy yet reverses the underlying collagen buildup itself. Within that reality, one option stands out as far more intensive than anything else available: a stem cell transplant that intentionally wipes out part of the immune system and rebuilds it. This piece explains what that actually involves, what a major trial found, and what else is being studied.
Looking for treatment options for scleroderma?
Browse open Scleroderma clinical trials near you! We'll handle the follow-up.
What's approved right now
Two drugs are approved specifically for lung scarring in scleroderma, not for skin thickening or other organ problems. Nintedanib is an antifibrotic drug, it slows down the scarring process that stiffens lung tissue over time. Tocilizumab works differently, through inflammation instead of scarring directly. Interestingly, tocilizumab didn't meaningfully improve skin thickness in its main trial, but it did help lung function, and that's actually why it got approved.
Beyond these two drugs, most scleroderma treatment relies on older medicines used off-label (not specifically for scleroderma), like mycophenolate and cyclophosphamide. This is where stem cell transplant comes in, as a more intensive option for people who need more than what these standard drugs can offer.
The stem cell transplant option
For people with severe scleroderma affecting the lungs or kidneys early on, doctors sometimes consider a stem cell transplant. Here's how it works: doctors give high doses of chemotherapy, sometimes combined with full-body radiation, to deliberately wipe out the person's existing bone marrow and immune system. Then they give back stem cells collected from that same person earlier, to rebuild everything from scratch. The goal is to essentially reset an immune system that's attacking the body.
A major study called the SCOT trial tested this against the standard treatment, cyclophosphamide, in 75 people with severe scleroderma. After about 4.5 years, 79% of people who got the transplant were alive with no major organ failure, compared to 50% of people who got standard treatment, a big difference.
Long-term follow-up at 6 to 11 years found the benefit held up over time. That said, this option does carry real trade-offs. It has a higher short-term risk than standard treatment, and doctors weigh that risk carefully against the potential long-term benefit for each person.
What researchers are studying now
- JAK inhibitors, a drug class already used in rheumatoid arthritis and other autoimmune conditions, are being explored for scleroderma's inflammatory and fibrotic components, though this research is earlier stage than the ILD-focused drugs already approved.
- Antifibrotic combinations are being tested to see whether pairing existing lung-focused drugs with other mechanisms can improve on what nintedanib and tocilizumab achieve alone.
- Refining who benefits most from transplant. Because SCOT's benefit came with real risk, current research is focused on identifying which patients are healthy enough, and early enough in disease, to make that trade-off worthwhile, rather than expanding who's eligible indiscriminately.
Why scleroderma research moves carefully
The intensity-versus-benefit problem. Stem cell transplant is the most effective single intervention shown in a major trial, and also carries real mortality risk. Research now has to work out patient selection carefully rather than just proving the treatment can work in general.
The organ-by-organ problem. Because approved drugs target specific complications (lung scarring, for now) rather than the disease broadly, there's no single trial that can test "does this help scleroderma," every study has to pick a specific organ or measure to focus on, which fragments the research landscape.
The comparison problem. With multiple older immunosuppressants already in informal use, any new trial has to be designed against a moving target of what "standard care" even means, since practice varies by clinic and by how severe someone's disease is.
Does scleroderma affect more than skin and lungs?
Yes, often significantly. Raynaud's phenomenon affects the vast majority of systemic sclerosis patients and can be genuinely painful and disruptive day to day, not just a cosmetic color change in the fingers. Gastrointestinal involvement, from reflux to motility problems, is also common and can affect nutrition and daily comfort. If GI symptoms or Raynaud's episodes are affecting your daily life, they're worth raising directly with your rheumatologist, since management options exist even outside of a clinical trial.
How to find a scleroderma study through our platform
Eligibility here depends heavily on severity and which organs are affected, so start your search there rather than by treatment type alone. Right now, for example, you can find a study testing rapcabtagene autoleucel, a CAR T-cell therapy for diffuse cutaneous systemic sclerosis, as well as a Phase 2/3 study testing belimumab, a biologic already used for lupus, specifically for scleroderma-related lung disease. Our scleroderma clinical trials page always shows the current recruiting studies. Applying takes about 5 minutes, and a coordinator follows up to confirm fit.
Common myths, cleared up
"Scleroderma just means tight skin."
Skin thickening is the most visible feature, but systemic sclerosis can affect the lungs, heart, kidneys, and digestive tract, sometimes more seriously than the skin itself.
"If you have CREST syndrome, you have a completely different disease from scleroderma."
CREST is an older name for limited cutaneous systemic sclerosis, a subtype of scleroderma, not a separate condition.
"A stem cell transplant is basically a cure."
It's the most effective single intervention studied so far for a specific severe subset of patients, but it carries real risk and isn't offered as a first-line option or a guaranteed fix.
Common questions
What are the symptoms of scleroderma? Skin thickening and tightening is the most visible sign, but symptoms also commonly include Raynaud's phenomenon, fingers turning white or blue in cold or stress, joint pain, fatigue, and digestive issues like reflux, depending on which organs are affected.
Is scleroderma genetic? It's not directly inherited, and most people with scleroderma have no family history of it. Genetics likely play some role in risk, since certain genes are more common in people who develop it, but environmental factors matter too, and researchers haven't fully worked out how the two interact.
How is scleroderma diagnosed? Diagnosis usually starts with a physical exam looking at skin changes and Raynaud's symptoms, followed by blood tests checking for specific antibodies linked to scleroderma. A skin biopsy or lung function tests may follow, depending on which organs seem affected, since there's no single test that confirms it on its own.
What are the early signs of scleroderma? Raynaud's phenomenon, fingers turning white or blue in cold or stress, is often the earliest sign, sometimes appearing years before other symptoms. Skin tightness or puffiness in the fingers and hands, along with fatigue and joint stiffness, are also common early signals.
Is there a cure for scleroderma? Not currently. Treatment focuses on managing whichever organs are affected and slowing progression, and no approved therapy reverses the underlying collagen buildup once it's happened.
Is stem cell transplant available to any scleroderma patient who wants it? No. It's generally reserved for people with severe, early diffuse disease affecting major organs, given its real risks, and the decision is made carefully between patient and specialist, not offered as a routine option.